2seventy Bio, INC Form 4 insider transactions
Victoria Eatwell, CFO of 2seventy bio, reports acquisition and disposal of company stock, including shares sold to cover tax obligations.
Director Marcela V. Maus reported the acquisition of stock and option awards in 2seventy bio, Inc.
Director Wei Lin of 2seventy bio, Inc. reports the acquisition of restricted stock units and stock options, as well as the disposal of existing shares.
Director Sarah Glickman of 2seventy bio, Inc. reports the acquisition of stock options and vesting of restricted stock units (RSUs) on June 10, 2024.
Director Charles W. Newton reports acquisition of stock and options in 2seventy bio, Inc.
Director Denice Torres acquired shares and stock options in 2seventy bio, Inc. on June 10, 2024.
Casdin Capital, along with related entities and individuals, reports acquiring 6,025 shares of 2seventy bio, Inc., along with stock options and economic exposure through swap agreements.
Victoria Eatwell, CFO of 2seventy bio, sold 1,167 shares of common stock on June 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Jessica Snow, a Senior Vice President at 2seventy bio, sold 649 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Jessica Snow, a Senior Vice President at 2seventy bio, sold 15 shares of common stock to cover tax withholding obligations.
Jessica Snow, a Senior Vice President at 2seventy bio, Inc., acquired common stock and stock options as part of an equity compensation plan.
Victoria Eatwell, CFO of 2seventy bio, acquired shares and stock options in the company on April 1, 2024.
William D. Baird III, CEO of 2seventy bio, Inc., received stock options and restricted stock units on April 1, 2024, according to a recent SEC filing.
Casdin Capital, along with related entities and Eli Casdin, reports acquiring 40,000 shares of 2seventy bio, Inc. at an average price of $5.0998 per share, increasing their indirect holdings.
Casdin Capital, along with related entities and individuals, has increased its holdings in 2seventy bio, Inc. (TSVT) through a series of open market purchases, while also engaging in total return swap agreements.
Director Charles W. Newton reports acquisition of common stock and stock options in 2seventy bio, Inc.